Ke Wang

机构：Peking University, Peking University People's Hospital · ORCID：0000-0003-4654-8429

发表论文 22 篇 · 总被引 619 次 · h-index 8

代表论文

• Radiomic Features at Contrast-enhanced CT Predict Recurrence in Early Stage Hepatocellular Carcinoma: A Multi-Institutional Study (2020 · Radiology · 被引 282)
• Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial (2022 · Journal for ImmunoTherapy of Cancer · 被引 218)
• Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer (2020 · Annals of Surgical Oncology · 被引 17)
• A Novel Nomogram for the Preoperative Prediction of Edmondson-Steiner Grade III-IV in Hepatocellular Carcinoma Patients (2023 · Journal of Hepatocellular Carcinoma · 被引 16)
• Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B‐related hepatocellular carcinoma (2022 · Journal of Gastroenterology and Hepatology · 被引 14)
• CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes (2021 · Clinical Pharmacology & Therapeutics · 被引 12)